Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Advair Diskus)
554 results
  • Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. [Review]
    Respir Med. 2022 Aug-Sep; 200:106918.Maltais F, Vogelmeier CF, … Naya IP
  • Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a large, multicentre, multi-national, randomised, double-blind, 24-week trial. EMAX evaluated the efficacy and safety of dual bronchodilator therapy with umeclidinium bromide (UMEC)/vilanterol (VI) versus monotherapy with either UMEC or salmeterol (SAL) in symptomatic patients with chronic obstructive pulmonary disease …
  • A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination. [Review]
    Expert Rev Respir Med. 2022 05; 16(5):529-540.Kilaru SC, Bansal AG, … Gogtay JA
  • Fluticasone propionate/formoterol fumarate (FP/FORM) is one of the newer combinations among inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA) combination formulations currently available. To evaluate the efficacy and safety of this FP/FORM combination, it is important to review all the available evidence and take a comprehensive look at the current and relevant data in the patient po…
  • Salmeterol-Fluticasone: The Role Revisited. [Journal Article]
    J Assoc Physicians India. 2022 Dec; 69(12):11-12.Vora A, Dhar R, … Gaonkar P
  • Apart from the individual diseases, some patients also show overlapping manifestations of asthma and COPD. Nevertheless, the diagnosis of COPD is often delayed due to inaccessibility to spirometry; the prevalence of the asthma COPD overlap phenotype is rather high given the exposure to biomass smoke. Furthermore, the rates of exacerbations are twice as high compared to the patients with either of…
  • Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma. [Journal Article]
    Expert Rev Respir Med. 2022 02; 16(2):183-195.Pelaia C, Crimi C, … Pelaia G
  • Asthma symptoms can be relieved through a maintenance treatment combining long-acting β2-agonist and inhaled corticosteroids (LABA/ICS). However, for patients with inadequately controlled asthma, the LABA/ICS combination might not be sufficient, and clinical guidelines recommend the administration of inhaled long-acting muscarinic antagonists (LAMA) as an add-on therapy to better control asthma a…
  • Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety. [Journal Article]
    Respir Med. 2021 Nov-Dec; 189:106645.Suissa S, Dell'Aniello S, Ernst P
  • CONCLUSIONS: In a real-world clinical setting of COPD treatment, a budesonide-formoterol inhaler was generally as effective at reducing the incidence of moderate-severe exacerbations as fluticasone-salmeterol. However, budesonide-formoterol was more effective than fluticasone-salmeterol at reducing the incidence of severe exacerbation and the risk of severe pneumonia, particularly in patients with higher blood eosinophil counts.
  • Hungarian adaptation and launch of the 2019 ARIA care pathways of allergic rhinitis in Hungary [Journal Article]
    Orv Hetil. 2020 12 06; 161(49):2059-2071.Kraxner H, Hirschberg A, Nékám K
  • Összefoglaló. Az allergiás betegségekben szenvedő emberek száma világszerte, köztük Magyarországon is növekszik. Az egészségügyi ellátórendszerek azon dolgoznak, hogy minél hatékonyabban tudják felhasználni a rendelkezésre álló forrásokat. Az Allergic Rhinitis and its Impact on Asthma (ARIA) szervezet célja az allergiás náthában szenvedő betegek ellátásának javítása, szakmai ajánlások készítése, …
New Search Next